中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2015年
6期
751-752,753
,共3页
糖尿病肾病%黄芪注射液%灯盏花素注射液%临床疗效
糖尿病腎病%黃芪註射液%燈盞花素註射液%臨床療效
당뇨병신병%황기주사액%등잔화소주사액%림상료효
Diabetic nephropathy%Astragalus injection%Breviscapine injection%Clinical efficacy
目的：探讨黄芪注射液与灯盏花素注射液联合治疗糖尿病肾病的临床疗效。方法：纳入2012年1月—2013年1月收治的80例糖尿病肾病患者，以随机数字表法分为观察组和对照组各40例。2组患者均接受常规治疗，观察组患者加用黄芪注射液与灯盏花素注射液联合治疗，对照组加用黄芪注射液治疗，观察2组患者的临床疗效。结果：观察组患者的总有效率为87．50％（35／40），对照组为75．00％（30／40），2组差异有统计学意义（P＜0．05）；观察组患者血尿素氮、尿清蛋白排泄率、血清肌酐等指标改善情况明显优于对照组，差异有统计学意义（ P＜0．05）；2组患者空腹血糖水平比较，差异无统计学意义（ P＞0．05）；2组患者不良反应发生率比较，差异无统计学意义（ P＞0．05）。结论：在糖尿病肾病的常规治疗基础上，加用黄芪注射液与灯盏花素注射液，有利于改善临床症状，不良反应少，安全、可靠，临床疗效优于加用黄芪注射液单药治疗，值得临床推广。
目的：探討黃芪註射液與燈盞花素註射液聯閤治療糖尿病腎病的臨床療效。方法：納入2012年1月—2013年1月收治的80例糖尿病腎病患者，以隨機數字錶法分為觀察組和對照組各40例。2組患者均接受常規治療，觀察組患者加用黃芪註射液與燈盞花素註射液聯閤治療，對照組加用黃芪註射液治療，觀察2組患者的臨床療效。結果：觀察組患者的總有效率為87．50％（35／40），對照組為75．00％（30／40），2組差異有統計學意義（P＜0．05）；觀察組患者血尿素氮、尿清蛋白排洩率、血清肌酐等指標改善情況明顯優于對照組，差異有統計學意義（ P＜0．05）；2組患者空腹血糖水平比較，差異無統計學意義（ P＞0．05）；2組患者不良反應髮生率比較，差異無統計學意義（ P＞0．05）。結論：在糖尿病腎病的常規治療基礎上，加用黃芪註射液與燈盞花素註射液，有利于改善臨床癥狀，不良反應少，安全、可靠，臨床療效優于加用黃芪註射液單藥治療，值得臨床推廣。
목적：탐토황기주사액여등잔화소주사액연합치료당뇨병신병적림상료효。방법：납입2012년1월—2013년1월수치적80례당뇨병신병환자，이수궤수자표법분위관찰조화대조조각40례。2조환자균접수상규치료，관찰조환자가용황기주사액여등잔화소주사액연합치료，대조조가용황기주사액치료，관찰2조환자적림상료효。결과：관찰조환자적총유효솔위87．50％（35／40），대조조위75．00％（30／40），2조차이유통계학의의（P＜0．05）；관찰조환자혈뇨소담、뇨청단백배설솔、혈청기항등지표개선정황명현우우대조조，차이유통계학의의（ P＜0．05）；2조환자공복혈당수평비교，차이무통계학의의（ P＞0．05）；2조환자불량반응발생솔비교，차이무통계학의의（ P＞0．05）。결론：재당뇨병신병적상규치료기출상，가용황기주사액여등잔화소주사액，유리우개선림상증상，불량반응소，안전、가고，림상료효우우가용황기주사액단약치료，치득림상추엄。
OBJECTIVE:To evaluate the clinical efficacy of astragalus injection plus breviscapine injection in treatment of diabetic nephropathy.METHODS:A total of 80 patients with diabetic nephropathy patients treated in our hospital from Jan.2012 to Jan.2013 were randomly divided into observation group and control group of 40 cases each. The observation group received routine therapy plus astragalus injection and Breviscapine injection while the control group received routine therapy plus astragalus injection alone.The clinical efficacy of the 2 groups was evaluated. RESUTLS: The effective rate was 87.50%( 35/40 ) for observation group vs.75%( 30/40 ) for control group, showing significant difference between 2 groups ( P<0.05 ) .The observation group had better improvement than did the control group in blood urea nitrogen ( BUN) , urinary albumin excretion rate( UAER) , serum creatinine and other indicators(P<0.05);there were no statistically significant difference in FBG levels and the incidence of adverse drug reactions between the two groups ( P >0.05 ) .CONCLUSIONS: Addition of astragalus injection and breviscapine injection to the routine therapy in treatment of diabetic nephropathy resulted in improvement in clinical symptoms, few adverse reaction, good safety and reliability, with better clinical efficacy than the addition of astragalus injection alone, thus the clinical use of astragalus injection and breviscapine injection added to the routine therapy in treatment of diabetic nephropathy is worthy of clinical recommendation.
